《新股消息》锦欣生殖(01951.HK)公开发售获近百倍认购上限8.54元定价
明日(25日)挂牌上市的锦欣生殖(01951.HK)公布配发结果,发售价定於每股8.54元,为其招股价区间上限,料集资净额28.08亿元,早前公司公布,集资所得约25%用於拓展及升级中国网络的现有辅助生殖医疗机构及招聘医疗专业人士,20%用於目前无经营的内地省份的额外辅助生殖医疗机构潜在收购,10%用於投资研发,20%用於辅助生殖服务服务链的辅助生殖服务提供商及业务潜在收购,15%用於改善品牌专注度以及中国及美国对辅助生殖服务的整体专注,其余余下10%用於营运资金及一般企业用途。
公司提供人工授孕服务,其公开发售部分录得99.26倍认购,即超购98.26倍,经重新分配後,相关部分最终发售股份数目近1.43亿股,占全球发售之40%;另国际发售部分亦获大幅超额认购。每手2,000股,一手中签率65%。摩根士丹利和中信里昂证券担任联席保荐人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.